子宫内膜异位症相关疼痛的药物干预:系统综述与网状Meta分析
该系统综述与网状Meta分析检索截至2024年7月22日的多个数据库,纳入31项随机对照试验共8665例患者,评估多种药物对子宫内膜异位症相关疼痛的疗效。结果显示,亮丙瑞林联合复方口服避孕药在改善盆腔痛方面最有效,elagolix和维生素C联合维生素E对痛经和性交痛最有效,孕三烯酮对非经期盆腔痛最有效。
要点
- 亮丙瑞林联合复方口服避孕药在改善子宫内膜异位症相关盆腔痛方面可能最有效。
- elagolix及维生素C联合维生素E可能最有效改善痛经和性交痛。
- 孕三烯酮在改善非经期盆腔痛方面可能优于安慰剂及其他干预措施。
核心结论
- 网状Meta分析提示,亮丙瑞林联合复方口服避孕药、elagolix、维生素C联合维生素E及孕三烯酮可能是缓解子宫内膜异位症相关盆腔痛、痛经、性交痛和非经期盆腔痛的最有效治疗选择。
- 未来研究应聚焦于在目标患者人群中开展更大规模、设计严谨的临床试验以进一步验证这些结果。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Embase、Web of Science和Cochrane对照试验注册库至2024年7月22日,并检索ClinicalTrials.gov但未发现额外数据。
- 纳入31项随机对照试验,共8665例患者,评估药物干预对子宫内膜异位症相关疼痛的疗效,遵循PRISMA指南。
主要发现
- 与安慰剂相比,亮丙瑞林联合复方口服避孕药(SMD -1.40,95% CI -2.41至-0.38)、地诺孕素(SMD -1.20,95% CI -1.78至-0.61)、亮丙瑞林单药(SMD -1.05,95% CI -1.64至-0.45)及复方口服避孕药(SMD -0.67,95% CI -1.25至-0.09)在改善子宫内膜异位症相关盆腔痛方面疗效显著更优。
- 亮丙瑞林联合复方口服避孕药成为最有效的治疗方式。
- elagolix及维生素C联合维生素E被确定为对痛经和性交痛最有效的干预措施。
- 对于非经期盆腔痛,孕三烯酮的疗效优于安慰剂及所有其他干预措施。
局限性
- 未来研究应聚焦于在目标患者人群中开展更大规模、设计严谨的临床试验以进一步验证这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of various medications for the treatment of endometriosis-related pain through a network meta-analysis. DATA SOURCES: A comprehensive search was conducted in PubMed, Embase, Web of Science, and the Cochrane Controlled Trials Register until July 22, 2024. We also searched ClinicalTrials.gov for additional data on recently completed trials or potentially eligible randomized controlled trials (RCTs) but found nothing. METHODS OF STUDY SELECTION: The analysis included randomized RCTs that used pharmacologic interventions for managing endometriosis-related pain. The primary efficacy outcome was endometriosis-associated pelvic pain, which included dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. The analysis adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines. TABULATION, INTEGRATION, AND RESULTS: A total of 31 RCTs involving 8,665 patients were included in the analysis. In terms of endometriosis-associated pelvic pain, four interventions demonstrated significantly greater efficacy compared with placebo: leuprolide combined with combined oral contraceptive pills (OCPs) (standardized mean difference [SMD] -1.40, 95% CI, -2.41 to -0.38), dienogest (SMD -1.20, 95% CI, -1.78 to -0.61), leuprolide alone (SMD -1.05, 95% CI, -1.64 to -0.45), and combined OCP (SMD -0.67, 95% CI, -1.25 to -0.09). Leuprolide combined with combined OCP emerged as the most effective treatment modality. In addition, elagolix and the combination of vitamin C and vitamin E were identified as the most effective interventions for dysmenorrhea and dyspareunia. For nonmenstrual pelvic pain, gestrinone demonstrated superior efficacy compared with placebo and all other interventions. CONCLUSION: This network meta-analysis indicates that leuprolide in combination with combined OCP, elagolix, vitamins C and E, and gestrinone may represent the most effective therapeutic options for alleviating endometriosis-associated pelvic pain, dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. These findings enhance our understanding of the relative efficacy of treatment strategies for pain associated with endometriosis. Future research should focus on conducting larger-scale and rigorously designed clinical trials within the target patient populations to further validate these results.
引用
- Kou L, Huang C, Xiao D, et al. Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis. Obstet Gynecol. 2025. PMID: 40373315. doi:10.1097/AOG.0000000000005923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。